Journal cover. (Molecules)
How might the novel coronavirus be prevented from entering a host cell in an effort to thwart infection? A team of biomedical scientists has made a discovery that points to a solution.
The scientists, led by Maurizio Pellecchia in the School of Medicine at the University of California, Riverside, report in the journal Molecules that two proteases — enzymes that break down proteins — located on the surface of host cells and responsible for processing viral entry could be inhibited. Such protease inhibition would prevent SARS-CoV2, the coronavirus responsible for COVID-19, from invading the host cell.
The research is featured as the cover story of the journal (Volume 25, Issue 10).
The outer surface of coronaviruses contains a critical protein called spike glycoprotein, or S-glycoprotein. Responsible for giving the coronavirus its typical crown shape, the S-glycoprotein is essential for the entry of viral particles into host cells. Host cell proteases, however, must first process or cut this viral surface protein to allow the virus to enter the cells.
Pellecchia’s lab and others have recognized that in addition to a previously identified protease called TMPRSS2, the new SARS-CoV2 coronavirus could also be processed by an additional human protease, called furin, for viral entry.
“The use of the host protease furin for processing is a common mechanism of cell entry by both viral fusion proteins and certain bacterial toxins,” said Pellecchia, a professor of biomedical sciences, who led the research team. “SARS-CoV2 uses this mechanism also. The nature of the ‘proteolytic cleavage’ in its S-glycoprotein can determine whether this virus can be transmitted across species, for example from bats or camels to humans.”
A fusion protein combines the attributes of more than one protein. Proteolytic cleavage refers to the process of breaking the peptide bonds between amino acids in a protein, which results in cutting the protein.
The coronavirus S-glycoprotein contains three cleavage sites that human host proteases process. The exact nature and sequence of these cleavage sites, and their respective processing proteases, can determine the level of pathogenicity and whether the virus can cross species.
Spotlight on inhibitors
Pellecchia explained that the anthrax toxin, similar to SARS-CoV2, requires processing by human furin to infect macrophages, a type of white blood cell. Using anthrax toxin as model system, his team found an inhibitor of both TMPRSS2 and furin in cellular and animal models can efficiently suppress cell entry by the toxin.
A clinical trial with COVID-19 patients recently began using the TMPRSS2 inhibitor camostat.
“We found, however, that camostat is a poor furin inhibitor,” Pellecchia said. “Our current study, therefore, calls for the development of additional protease inhibitors or inhibitor-cocktails that can simultaneously target both TMPRSS2 and furin and suppress SARS-CoV2 from entering the host cell.”
Pellecchia added that until now the presence of a furin cleavage site in SARS-CoV2 had been linked to increased pathogenicity. But genetic elimination of furin in cellular laboratory studies failed to stop viral entry, suggesting TMPRSS2 remains the most relevant protease.
Using peptide sequences from SARS-CoV2 S-glycoprotein, however, his team has now demonstrated the new mutations in this coronavirus strain resulted in efficient and increased processing of viral entry by furin and TMPRSS2.
“In other words, SARS-CoV2, unlike other less pathogenic strains, can more efficiently use both proteases, TMPRSS2 and furin, to start the invasion of host cells,” Pellecchia said. “While TMPRSS2 is more abundant in the lungs, furin is expressed in other organs, perhaps explaining why SARS-CoV2 is capable of invading and damaging multiple organs.”
Pellecchia’s lab has already identified potent and effective preclinical inhibitors of furin and demonstrated these inhibitors could be developed as potential COVID-19 therapeutics, perhaps in combination with drugs such as camostat, the TMPRSS2 inhibitor.
“We are seeking additional funding to pursue the design and development of dual inhibitors that can simultaneously target both TMPRSS2 and furin,” Pellecchia said. “The funding would allow us to explore new possible effective therapeutics against COVID-19 and support studies that could have far reaching applications to ward off possible future pandemics resulting from similar activating mutations in other viral strains.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Exercise Is Essential for a Strong Immune System—These Health Experts Explain How Movement Can Boost Immunityon March 2, 2021 at 1:55 pm
There's been no time in recent history when we've been more concerned with our immunity and fending off disease than during COVID-19. And as it turns out, getting moving might play a significant role ...
- Forecast of virus lasting beyond 2021 worrisomeon March 2, 2021 at 11:05 am
At a time when the world is struggling to make all-out efforts to curb or wipe out the virus from the face of the earth, a revelatory statement from WHO is startling. A senior official of the global h ...
- COVID-19—from mucosal immunology to IBD patientson February 19, 2021 at 5:04 am
Impact of immune suppression on SARS-CoV2 infections in IBD patients In regard of the frequent use of biologics and immune suppressors in patients with IBD, it appears central to delineate the ...
- Covid Variants: The Effectiveness of Vaccineson February 19, 2021 at 2:38 am
Professor of Glasgow University, David Bhella pointed out that wearing double masks could pose a greater risk depending on the situation if not used ...
- Opko Health (OPK) Q4 2020 Earnings Call Transcripton February 19, 2021 at 2:31 am
Q4 2020 Earnings CallFeb 18, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Effective therapeutics against COVID-19
- Claritas Pharmaceuticals (formerly Kalytera Therapeutics) to Focus on Development of R-107 as a ...on March 1, 2021 at 9:34 pm
Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.), (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the “Company” or “Claritas”) today announced that the Company will focus its ...
- How The Biden Administration Can Win The War Against Covid-19on February 25, 2021 at 12:49 pm
Biden promised as he took office that his Administration would deliver 100 million vaccinations in his first 100 days.
- Global Drug Discovery Outsourcing Market Analysis Report 2021: A Key Aspect to Develop Effective Treatments Against COVID-19 - ResearchAndMarkets.comon February 23, 2021 at 2:14 am
Feb 23, 2021-- The “Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Workflow (Lead Identification & Candidate Optimization, Others), by Therapeutics Area (Oncology, ...
- UNI91103, developed by UNION therapeutics A/S, selected as first agent for prophylactic COVID-19 "PROTECT-V" study in high-risk patientson February 22, 2021 at 9:03 am
UNI91103 is a nasal spray delivering niclosamide - a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir - to the ...
- Ensuring continued progress for development of COVID-19 therapeutics in childrenon February 18, 2021 at 1:25 pm
In contrast to DAAs where the activity against the virus is expected to be similar regardless of the host once similar concentrations are achieved, advancing host response modifiers as therapies for ...